Genmab: potential label expansion for Darzalex in Europe

(CercleFinance.com) - Danish biotech firm Genmab said that Janssen has submitted an application for marketing the Darzalex drug as treatment for newly diagnosed multiple myeloma patients.


The application to the European Medicines Agency (EMA) aims to broaden the existing marketing authorisation for Darzalex to include use in combination with lenalidomide and dexamethasone for patients who are not candidates for high-dose chemotherapy and autologous stem cell transplants, it said.

For the record, Genmab has granted J&J's Janssen an exclusive worldwide license to develop, manufacture and market Darzalex.

Copyright (c) 2019 CercleFinance.com. All rights reserved.